475 related articles for article (PubMed ID: 28501038)
1. [Superiority of 18F-FNa PET/CT for Detecting Bone Metastases in Comparison with Other Diagnostic Imaging Modalities].
Lapa P; Saraiva T; Silva R; Marques M; Costa G; Lima JP
Acta Med Port; 2017 Jan; 30(1):53-60. PubMed ID: 28501038
[TBL] [Abstract][Full Text] [Related]
2. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
[TBL] [Abstract][Full Text] [Related]
3. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
[TBL] [Abstract][Full Text] [Related]
4. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
Iagaru A; Mittra E; Dick DW; Gambhir SS
Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
[TBL] [Abstract][Full Text] [Related]
6. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
Gerety EL; Lawrence EM; Wason J; Yan H; Hilborne S; Buscombe J; Cheow HK; Shaw AS; Bird N; Fife K; Heard S; Lomas DJ; Matakidou A; Soloviev D; Eisen T; Gallagher FA
Ann Oncol; 2015 Oct; 26(10):2113-8. PubMed ID: 26202597
[TBL] [Abstract][Full Text] [Related]
7.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
8. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis.
Liu NB; Zhu L; Li MH; Sun XR; Hu M; Huo ZW; Xu WG; Yu JM
Asian Pac J Cancer Prev; 2013; 14(6):3647-52. PubMed ID: 23886160
[TBL] [Abstract][Full Text] [Related]
11. Bone metastases diagnosis possibilities in studies with the use of 18F-NaF and 18F-FDG.
Tarnawska-Pierścińska M; Hołody Ł; Braziewicz J; Królicki L
Nucl Med Rev Cent East Eur; 2011; 14(2):105-8. PubMed ID: 22219151
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Study Comparing
Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
[TBL] [Abstract][Full Text] [Related]
13. [Heterogeneity of bone metastases in a patient with breast cancer: case report illustrating the potential of combining various imaging techniques].
Withofs N; Collignon J; Rorive A; Jerusalem G; Hustinx R
Rev Med Liege; 2011; 66(5-6):288-90. PubMed ID: 21826964
[TBL] [Abstract][Full Text] [Related]
14. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.
Beheshti M; Rezaee A; Geinitz H; Loidl W; Pirich C; Langsteger W
J Nucl Med; 2016 Oct; 57(Suppl 3):55S-60S. PubMed ID: 27694173
[No Abstract] [Full Text] [Related]
16. Evaluation of bone-seeking novel radiotracer
Passah A; Tripathi M; Ballal S; Yadav MP; Kumar R; Roesch F; Meckel M; Sarathi Chakraborty P; Bal C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):41-49. PubMed ID: 27455986
[TBL] [Abstract][Full Text] [Related]
17. Comparison of
Zhang Y; Chen Y; Huang Z; Zhang L; Wan Q; Lei L
Contrast Media Mol Imaging; 2018; 2018():8271313. PubMed ID: 30254551
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.
Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA
Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313
[TBL] [Abstract][Full Text] [Related]
19. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
[TBL] [Abstract][Full Text] [Related]
20. Utility of 18F-fluorodeoxy glucose and 18F-sodium fluoride positron emission tomography/computed tomography in the diagnosis of medication-related osteonecrosis of the jaw: A preclinical study in a rat model.
Kim Y; Lee HY; Yoon HJ; Kim BS
J Craniomaxillofac Surg; 2016 Apr; 44(4):357-63. PubMed ID: 26880011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
